SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company developing novel therapies for a broad range of cancer indications, will host a corporate update call on January 8, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 outlook.
The company's lead product candidate is Galinpepimut-S (GPS), licensed from Memorial Sloan Kettering Cancer Center, and it targets the WT1 protein, which is present in an array of tumor types.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com